In a remarkable, ongoing success story, Foundation Medicine, Inc (FMI) began a quest to bring the latest science and technology to routine cancer care, and in just a few years the company went public (NASDAQ: FMI) and grew to become one of the preeminent genomic profiling laboratories in the country.
The company now provides 2 comprehensive genomic profiles for cancer (FoundationOne® for solid tumors, and FoundationOne Heme for hematologic malignancies, sarcomas, and select pediatric cancers), and by the end of 2013 had tested over 10,000 patient samples. FMI partners with academic researchers, biopharmaceutical companies, and oncologists to refine the genomic information needed by for oncologists to make informed decisions about patient treatment.
At the 2014 AMP Meeting, FMI’s Research Director of Molecular Biology & Sequencing, Dr Geoff Otto, discussed FMI’s unique approach to assay development using targeted next-generation sequencing to generate molecular information that will better inform cancer categorization and treatment decisions. He described the challenges sample collection protocols create for genomic studies, and, using the example of a traditionally archived tissue specimen, illustrated how these results can complement FISH, IHC, and other data provided by the pathologist.
IDT has been collaborating with Foundation Medicine to provide pooled target capture probes (DNA baits) that ensure uniform coverage across the genomic loci that the FMI assays target.
Access the presentation here.